pargyline and curcumin

pargyline has been researched along with curcumin in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Cai, P; Kong, LY; Li, F; Liu, QH; Wang, J; Wang, XB; Wu, JJ; Yang, HL; Yang, XL1
Ding, Y; Hou, JW; Kang, P; Lan, JS; Liu, Y; Xie, SS; Zhang, T; Zhang, XY1
Cheng, M; Guo, J; Jiang, N; Li, Q; Liang, N; Liu, J; Nong, X; Pang, C; Qin, Y; Tang, C; Tang, W; Xie, SS; Zhang, Z1

Other Studies

3 other study(ies) available for pargyline and curcumin

ArticleYear
Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
    European journal of medicinal chemistry, 2017, Sep-29, Volume: 138

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Coumarins; Dose-Response Relationship, Drug; Drug Design; Humans; Male; Mice; Mice, Inbred Strains; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; PC12 Cells; Protein Aggregates; Rats; Structure-Activity Relationship

2017
Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
    European journal of medicinal chemistry, 2017, Oct-20, Volume: 139

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Coumarins; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; PC12 Cells; Protein Aggregates; Pyridinium Compounds; Rats; Structure-Activity Relationship

2017
Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
    European journal of medicinal chemistry, 2020, Sep-15, Volume: 202

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line, Tumor; Cell Survival; Clorgyline; Dose-Response Relationship, Drug; Drug Design; Humans; Indans; Male; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Peptide Fragments; Protein Aggregates; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship

2020